The use of Pyridostigmine bromide in the treatment of fatigue secondary to COVID-19

Phase 3

• Conditions: Post-Viral Fatigue Syndrome; COVID-19; C01.925

• Registration Number: RBR-107j3g4v
• Lead Sponsor: niversidade Federal Fluminense

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-08-11
• Study Completion: 2023-08-22
• Last Update Posted: 22 August 2023

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Individuals with a recent history of SARS Cov2 infection, confirmed by positive PCR; age between 18 and 65 years; patients who maintain permanent symptoms, mainly fatigue, after 4 weeks of the onset of the illness

Exclusion Criteria

Individuals with some type of motor or mental disability that prevents the performance of the proposed tests; pregnant women; subjects with known hypersensitivity to pyridostigmine; individuals with conditions that contraindicate the use of pyridostigmine, such as glaucoma, asthma and urinary obstruction; patients with heart rhythm different from sinus rhythm, with atrial fibrillation, frequent ventricular and/or supraventricular ectopy

Study & Design

• Study Type: Intervention
• Study Design: Not specified